Aaron Cowen’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,748,141
| Closed | -$67.2M | – | 108 |
|
|
2023
Q2 | $67.2M | Buy |
1,748,141
+179,344
| +11% | +$4.61M | 3.59% | 8 |
|
|
2023
Q1 | $36.3M | Buy |
1,568,797
+123,967
| +9% | +$2.96M | 1.53% | 25 |
|
|
2022
Q4 | $37.9M | Buy |
1,444,830
+54,830
| +4% | +$1.21M | 1.59% | 27 |
|
|
2022
Q3 | $27.3M | Sell |
1,390,000
-394,200
| -22% | -$7.91M | 1.13% | 36 |
|
|
2022
Q2 | $31.2M | Buy |
1,784,200
+350,000
| +24% | +$5.49M | 1.19% | 34 |
|
|
2022
Q1 | $23.5M | Buy |
1,434,200
+186,732
| +15% | +$2.54M | 0.72% | 44 |
|
|
2021
Q4 | $20.3M | Buy |
1,247,468
+200,000
| +19% | +$2.85M | 0.39% | 51 |
|
|
2021
Q3 | $13.4M | Buy |
1,047,468
+79,445
| +8% | +$1.05M | 0.23% | 57 |
|
|
2021
Q2 | $13.7M | Buy |
968,023
+418,408
| +76% | +$6.69M | 0.2% | 73 |
|
|
2021
Q1 | $8.54M | Buy |
549,615
+23,160
| +4% | +$378K | 0.13% | 77 |
|
|
2020
Q4 | $8.35M | Buy |
526,455
+298,199
| +131% | +$4.5M | 0.12% | 65 |
|
|
2020
Q3 | $2.77M | Buy |
228,256
+67,676
| +42% | +$907K | 0.05% | 75 |
|
|
2020
Q2 | $1.85M | Buy |
+160,580
| New | +$2.21M | 0.04% | 74 |
|
Aaron Cowen's KDNY Position: Q3 2023 in Review
Aaron Cowen sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,748,141 shares — an estimated $67.2M sold.
Aaron Cowen first reported a position in KDNY in Q2 2020 and held it in 13 quarters. The position peaked at $67.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Aaron Cowen reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Aaron Cowen sold 1,748,141 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $67.2M.
- Aaron Cowen first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2020 and held it in 13 quarters.
- Aaron Cowen's Chinook Therapeutics, Inc. Common Stock position peaked at $67.2M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Suvretta Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.